Moving Toward Personalized Care: Liquid Biopsy Predicts Response to Cisplatin in an Unusual Case of BRCA2-Null Neuroendocrine Prostate Cancer

Clin Genitourin Cancer. 2016 Apr;14(2):e233-6. doi: 10.1016/j.clgc.2015.12.023. Epub 2015 Dec 24.
No abstract available

Keywords: Cell-free DNA; DNA damage repair; Precision medicine; Small cell carcinoma; ctDNA.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / therapeutic use
  • BRCA2 Protein / genetics*
  • Carcinoma, Neuroendocrine / drug therapy*
  • Carcinoma, Neuroendocrine / genetics
  • Cisplatin / administration & dosage*
  • Cisplatin / therapeutic use
  • Gene Deletion
  • Humans
  • Male
  • Middle Aged
  • Precision Medicine
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / genetics
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • BRCA2 Protein
  • BRCA2 protein, human
  • Cisplatin